| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on October 26, 2004
From the Department of Diagnostic Radiology, Aachen Technical University, Aachen, Germany (E.S., A.B., M.K., R.W.G.); EPIX Pharmaceuticals, Cambridge, Mass (A.J.W., E.C.P., P.B.G.); and Departments of Medicine (Cardiovascular Division) (R.M.B., W.J.M.) and Radiology (W.J.M.), Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Mass. * To whom correspondence should be addressed. E-mail: spuenti{at}rad.rwth-aachen.de.
Background--The differential diagnosis of acute chest pain is challenging, especially in patients with normal ECG findings, and may include coronary thrombosis or pulmonary emboli. The aim of this study was to investigate the novel fibrin-specific contrast agent EP-2104R for molecular targeted MR imaging of coronary thrombosis and pulmonary emboli. Methods and Results--Fresh clots were engineered ex vivo from human blood and delivered in the lungs and coronary arteries of 7 swine. Subsequent molecular MR imaging was performed with a navigator-gated free-breathing and cardiac-triggered 3D inversion-recovery black-blood gradient-echo sequence before and after systemic administration of 7.5 µmol/kg EP-2104R. Two swine served as the control group. MR images were analyzed by 2 investigators, and contrast-to-noise ratio and gadolinium concentration in the clots were assessed. Before contrast media application, no thrombi were visible. After contrast administration, all 32 pulmonary emboli, 3 emboli in the right heart, and 5 coronary thrombi were selectively visualized as white spots with a mean contrast-to-noise ratio of 32±19. The average gadolinium concentration from all 3 types of thrombi was 144±79 µmol/L. Conclusions--Molecular MR imaging with the fibrin-targeted contrast-agent EP-2104R allows selective visualization of acute coronary, cardiac, and pulmonary thrombi.
Revised on December 1, 2004
Accepted on December 2, 2004
Molecular Magnetic Resonance Imaging of Coronary Thrombosis and Pulmonary Emboli With a Novel Fibrin-Targeted Contrast Agent
Elmar Spuentrup MD*,
This article has been cited by other articles:
![]() |
R.-J. J.H.M. Miserus, M. V. Herias, L. Prinzen, M. B.I. Lobbes, R.-J. Van Suylen, A. Dirksen, T. M. Hackeng, J. W.M. Heemskerk, J. M.A. van Engelshoven, M. J.A.P. Daemen, et al. Molecular MRI of Early Thrombus Formation Using a Bimodal {alpha}2-Antiplasmin-Based Contrast Agent J. Am. Coll. Cardiol. Img., August 1, 2009; 2(8): 987 - 996. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Lockie, E. Nagel, S. Redwood, and S. Plein Use of Cardiovascular Magnetic Resonance Imaging in Acute Coronary Syndromes Circulation, March 31, 2009; 119(12): 1671 - 1681. [Full Text] [PDF] |
||||
![]() |
M. Nahrendorf, D. E. Sosnovik, B. A. French, F. K. Swirski, F. Bengel, M. M. Sadeghi, J. R. Lindner, J. C. Wu, D. L. Kraitchman, Z. A. Fayad, et al. Multimodality Cardiovascular Molecular Imaging, Part II Circ Cardiovasc Imaging, January 1, 2009; 2(1): 56 - 70. [Full Text] [PDF] |
||||
![]() |
C. von zur Muhlen, D. von Elverfeldt, J.A. Moeller, R.P. Choudhury, D. Paul, C.E. Hagemeyer, M. Olschewski, A. Becker, I. Neudorfer, N. Bassler, et al. Magnetic Resonance Imaging Contrast Agent Targeted Toward Activated Platelets Allows In Vivo Detection of Thrombosis and Monitoring of Thrombolysis Circulation, July 15, 2008; 118(3): 258 - 267. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. A. Jaffer, P. Libby, and R. Weissleder Molecular Imaging of Cardiovascular Disease Circulation, August 28, 2007; 116(9): 1052 - 1061. [Full Text] [PDF] |
||||
![]() |
T. Saam, T. S. Hatsukami, N. Takaya, B. Chu, H. Underhill, W. S. Kerwin, J. Cai, M. S. Ferguson, and C. Yuan The Vulnerable, or High-Risk, Atherosclerotic Plaque: Noninvasive MR Imaging for Characterization and Assessment Radiology, July 1, 2007; 244(1): 64 - 77. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. P. Stracke, M. Katoh, A. J. Wiethoff, E. C. Parsons, P. Spangenberg, and E. Spuntrup Molecular MRI of Cerebral Venous Sinus Thrombosis Using a New Fibrin-Specific MR Contrast Agent Stroke, May 1, 2007; 38(5): 1476 - 1481. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Sosnovik, M. Nahrendorf, and R. Weissleder Molecular Magnetic Resonance Imaging in Cardiovascular Medicine Circulation, April 17, 2007; 115(15): 2076 - 2086. [Full Text] [PDF] |
||||
![]() |
E. Escolar, G. Weigold, A. Fuisz, and N. J. Weissman New imaging techniques for diagnosing coronary artery disease. Can. Med. Assoc. J., February 14, 2006; 174(4): 487 - 495. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sirol, V. Fuster, J. J. Badimon, J. T. Fallon, J.-F. Toussaint, and Z. A. Fayad Chronic Thrombus Detection With In Vivo Magnetic Resonance Imaging and a Fibrin-Targeted Contrast Agent Circulation, September 13, 2005; 112(11): 1594 - 1600. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Spuentrup, B. Fausten, S. Kinzel, A. J. Wiethoff, R. M. Botnar, P. B. Graham, S. Haller, M. Katoh, E. C. Parsons Jr, W. J. Manning, et al. Molecular Magnetic Resonance Imaging of Atrial Clots in a Swine Model Circulation, July 19, 2005; 112(3): 396 - 399. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |